Clinical trial
Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and…
NCT00338299 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00338299 |
|---|---|
| Title | Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia |
| Official title | An Open-Label Pilot Study to Evaluate the Effects of Alternate Dosing of PROCRIT (Epoetin Alfa) in the Treatment of Patients With Cancer and Chemotherapy Induced Anemia (60,000 Units Weekly for Four Weeks Followed by 60,000 Units Every Two Weeks) |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Ortho Biotech Products, L.P. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anemia, Chemotherapy |
| Intervention type | Drug |
| Interventions | Epoetin alfa |
| Enrollment | 51 |
| Start date | Aug 1, 2003 |
| Completion | Apr 1, 2004 |
| First posted | Jun 20, 2006 |
| Last update posted | May 23, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: